300482.SHE Guangzhou Wondfo Biotech Co Ltd

The Graham number of Guangzhou Wondfo Biotech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for Guangzhou Wondfo Biotech Co Ltd yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China and internationally. The company offers rapid test kits for COVID-19, drug of abuse, tumor marker, infectious disease, fertility, blood/serum/plasma test, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, ga…

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

Guangzhou Wondfo Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

2.63%

Forward dividend

0.22 CNY

Payout ratio

-

Ex-dividend date

Jun 2, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Last stock split: 1.3:1 on May 26, 2021.

Company name

Guangzhou Wondfo Biotech Co Ltd

Ticker

300482.SHE

ISIN

CNE100002102

Exchange

Shenzhen Stock Exchange

Sector

Healthcare

Industry

Health Care Equipment & Supplies

Employees

2,443

Fiscal year end

December

Address

No.8 Lizhishan Road, Guangzhou, China, 510641

Phone

86 40 0830 8768

Website

wondfo.com.cn

About Guangzhou Wondfo Biotech Co Ltd

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China and internationally. The company offers rapid test kits for COVID-19, drug of abuse, tumor marker, infectious disease, fertility, blood/serum/plasma test, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease, as well as Finecare FIA Meter X2, a 16-channel fluorescence immunoassay analyzing system; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; blood gas biochemical analyzers and blood gas analyzers; molecular diagnostics platform; pathology straining system; and HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.

• Mr. Zhongxiong PengGM & Director · born 1974
• Ms. Fang Xia YuCFO & Deputy GM · born 1976
• Mr. Yaping ZhaoDeputy General Manager & Non-Independent Director · born 1977
• Ms. Hong HuBoard Secretary · born 1983
• Ms. Ke Ren KangDeputy General Manager · born 1976
• Cai Mei PengAccounting Supervisor